LogicBio Therapeutics (LOGC) Misses Q3 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts LOGC Hot Sheet
Join SI Premium – FREE
LogicBio Therapeutics (NASDAQ: LOGC) reported Q3 EPS of ($0.07).
For earnings history and earnings-related data on LogicBio Therapeutics (LOGC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Arm Holdings (ARM) Tops Q2 EPS by 5c, Beats on Revenue; Offers Q3 Guidance
- Qualcomm (QCOM) Reports In-Line Q4 EPS, Beats on Revenue; Offers Q1 Guidance
- ArcBest Corp (ARCB) PT Lowered to $146 at TD Cowen
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
